Two hundred and eight patients from a multicenter, prospective cohort of patients with metastatic castration-resistant prostate cancer (CRPC) with available RNA sequencing data were analyzed for tumor FAP mRNA expression, and its association with overall survival (OS) and NE tumor features was investigated.
Twenty-one patients (10%) were found to have high FAP mRNA expression. Compared to the rest, this subset had a proportionally higher exposure to taxanes and AR signaling inhibitors (abiraterone or enzalutamide) and was characterized by active NE signaling, evidenced by high NEPC- and low AR-gene expression scores. These patients with high tumor mRNA FAP expression had a more aggressive clinical course and significantly shorter survival (12 months) compared to those without altered FAP expression (28 months, log-rank p = 0.016).
FAP expression may serve as a valuable NE marker indicating a worse prognosis in patients with metastatic CRPC.
来自多中心的两百八个病人,转移性去势抵抗性前列腺癌(CRPC)患者的前瞻性队列与可用的RNA测序数据分析肿瘤FAPmRNA表达,并研究了其与总生存期(OS)和NE肿瘤特征的关系。
发现21名患者(10%)具有高FAPmRNA表达。与其他相比,该子集对紫杉烷类和AR信号抑制剂(阿比特龙或恩扎鲁他胺)的暴露比例更高,其特征是活跃的NE信号,高NEPC-和低AR-基因表达得分证明。与未改变FAP表达的患者相比,这些具有高FAPmRNA表达的患者具有更积极的临床病程和明显更短的生存期(12个月)(28个月,对数秩p=0.016)。
FAP表达可作为有价值的NE标志物,表明转移性CRPC患者的预后较差。